{
  "metadata": {
    "timestamp": "2025-12-16T19:13:42.458182",
    "genes": [
      "POSTN",
      "KIAA1211L",
      "CPNE4",
      "HMGA2",
      "TRPM8",
      "CYTOR",
      "RGS6",
      "RPH3A",
      "CCN4",
      "ADAMTS9-AS1",
      "SPRY1",
      "LEF1",
      "VAT1L",
      "COL22A1",
      "MIR4435-2HG",
      "AC000065.1",
      "CPED1",
      "ARHGAP6",
      "TRPM3",
      "ANGPT1",
      "ALK",
      "CA2",
      "SERPINE1",
      "CHRM3-AS2",
      "ITGA3",
      "KIRREL3",
      "RUBCNL",
      "SLA",
      "CCDC175",
      "SHISA6",
      "AC064875.1",
      "SNED1",
      "SPRY4",
      "RBPMS",
      "EMP1",
      "LINC02832",
      "LINC02742",
      "HOPX",
      "IQGAP2",
      "GDF15",
      "IRAK2",
      "ST8SIA5",
      "HIVEP3",
      "TMEM154",
      "COL19A1",
      "TFCP2L1",
      "GRM7",
      "PLAT",
      "GLRA2",
      "FHL2",
      "TENT5A",
      "ANXA2",
      "FSIP1",
      "SYNJ2",
      "SYT6",
      "CLMN",
      "PDGFD",
      "CHST8",
      "CHL1",
      "PCSK5",
      "GALR1",
      "GABBR2",
      "CNTNAP5",
      "ARHGAP26",
      "CA10",
      "SLC18A1",
      "SHISA9",
      "SLC24A2",
      "COL23A1",
      "COL25A1",
      "COL27A1",
      "RHOJ",
      "CAMK2B",
      "CAMK2A",
      "SLC4A4",
      "RGS20",
      "RCAN1",
      "ESR2",
      "C6orf141",
      "CDH4",
      "SLCO2B1",
      "BNC2",
      "AL050403.2",
      "DNAH9",
      "SOX1-OT",
      "EGR1",
      "SPRY2",
      "EPHA3",
      "PPP1R1C",
      "AL121917.1",
      "SCG2",
      "AC090791.1",
      "WNT16",
      "IL27RA",
      "MBNL3",
      "ADAM19",
      "IL1RAP",
      "AC004828.2",
      "AC011287.1",
      "WIPF3",
      "LINC01776",
      "HS3ST5",
      "INSYN2A",
      "JAG1",
      "NPR3",
      "AC124254.2",
      "NPY1R",
      "TRIB3",
      "UNC13C",
      "METTL7B",
      "AC002454.1",
      "VAV3",
      "NTSR1",
      "TSPAN18",
      "TPRG1",
      "KLHL29",
      "VSNL1",
      "LINC01949"
    ],
    "context": "malignant glioblastoma cells",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "glioblastoma_ds_auto",
    "query": "10_AC_gliosis_like_2",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "## Question\n\nPerform comprehensive literature analysis for the following gene list in the specified biological context.\n\n**Gene List**: [\"POSTN\", \"KIAA1211L\", \"CPNE4\", \"HMGA2\", \"TRPM8\", \"CYTOR\", \"RGS6\", \"RPH3A\", \"CCN4\", \"ADAMTS9-AS1\", \"SPRY1\", \"LEF1\", \"VAT1L\", \"COL22A1\", \"MIR4435-2HG\", \"AC000065.1\", \"CPED1\", \"ARHGAP6\", \"TRPM3\", \"ANGPT1\", \"ALK\", \"CA2\", \"SERPINE1\", \"CHRM3-AS2\", \"ITGA3\", \"KIRREL3\", \"RUBCNL\", \"SLA\", \"CCDC175\", \"SHISA6\", \"AC064875.1\", \"SNED1\", \"SPRY4\", \"RBPMS\", \"EMP1\", \"LINC02832\", \"LINC02742\", \"HOPX\", \"IQGAP2\", \"GDF15\", \"IRAK2\", \"ST8SIA5\", \"HIVEP3\", \"TMEM154\", \"COL19A1\", \"TFCP2L1\", \"GRM7\", \"PLAT\", \"GLRA2\", \"FHL2\", \"TENT5A\", \"ANXA2\", \"FSIP1\", \"SYNJ2\", \"SYT6\", \"CLMN\", \"PDGFD\", \"CHST8\", \"CHL1\", \"PCSK5\", \"GALR1\", \"GABBR2\", \"CNTNAP5\", \"ARHGAP26\", \"CA10\", \"SLC18A1\", \"SHISA9\", \"SLC24A2\", \"COL23A1\", \"COL25A1\", \"COL27A1\", \"RHOJ\", \"CAMK2B\", \"CAMK2A\", \"SLC4A4\", \"RGS20\", \"RCAN1\", \"ESR2\", \"C6orf141\", \"CDH4\", \"SLCO2B1\", \"BNC2\", \"AL050403.2\", \"DNAH9\", \"SOX1-OT\", \"EGR1\", \"SPRY2\", \"EPHA3\", \"PPP1R1C\", \"AL121917.1\", \"SCG2\", \"AC090791.1\", \"WNT16\", \"IL27RA\", \"MBNL3\", \"ADAM19\", \"IL1RAP\", \"AC004828.2\", \"AC011287.1\", \"WIPF3\", \"LINC01776\", \"HS3ST5\", \"INSYN2A\", \"JAG1\", \"NPR3\", \"AC124254.2\", \"NPY1R\", \"TRIB3\", \"UNC13C\", \"METTL7B\", \"AC002454.1\", \"VAV3\", \"NTSR1\", \"TSPAN18\", \"TPRG1\", \"KLHL29\", \"VSNL1\", \"LINC01949\"]\n\n**Biological Context**: malignant glioblastoma cells\n\n**Analysis Strategy**:\n1. Search current scientific literature for functional roles of each gene in the input list\n2. Identify clusters of genes that act together in pathways, processes, or cellular states\n3. Treat each cluster as a potential gene program within the list\n4. Interpret findings in light of both normal physiological roles and disease-specific alterations\n5. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant.\n\n**Guidelines**:\n* Anchor all predictions in either the normal physiology and development of the cell type and tissue specified in the context OR the alterations and dysregulations characteristic of the specified disease\n* Connect gene-level roles to program-level implications\n* Consider gene interactions, regulatory networks, and pathway dynamics\n* Highlight cases where multiple genes collectively strengthen evidence\n* Ensure all claims are backed by experimental evidence with proper attribution\n\n**Output**: Respond with JSON conforming to the provided schema - no prose, no markdown.  If you are unable to respond with JSON alone, make sure the text includes tables or fragments of schema compliant that unambiguously capture the elements and their associations that would be captured if returning JSON schema.\n\n```json\n{\n    \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n    \"title\": \"Gene Program Functional Analysis\",\n    \"description\": \"Comprehensive literature-based functional analysis of gene lists in specific biological contexts. Perform systematic analysis to identify gene programs - clusters of genes acting together in pathways, processes, or cellular states. For each program, predict functional implications for the specified cell type in the context of the provided disease and tissue environment. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant. Rank predictions higher when multiple genes from input list act in same process and when most/all required pathway components are present.\",\n    \"type\": \"object\",\n    \"required\": [\n        \"context\",\n        \"input_genes\",\n        \"programs\",\n        \"version\"\n    ],\n    \"definitions\": {\n        \"atomic_term\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"name\",\n                \"citation\",\n                \"genes\"\n            ],\n            \"properties\": {\n                \"name\": {\n                    \"type\": \"string\",\n                    \"description\": \"A minimal component of the gene program, representing a single biological process or cell component.\"\n                },\n                \"citations\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"$ref\": \"#/definitions/citation\"\n                    },\n                    \"description\": \"list of citations supporting the role of the listed genes in the name biological process or cell component\"\n                },\n                \"genes\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"Genes of the program whose products are involved in this biological process or cell component.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"citation\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"source_id\"\n            ],\n            \"properties\": {\n                \"source_id\": {\n                    \"type\": \"string\"\n                },\n                \"notes\": {\n                    \"type\": \"string\",\n                    \"description\": \"Why this citation supports the claim.\"\n                }\n            },\n            \"additionalProperties\": false\n        }\n    },\n    \"properties\": {\n        \"context\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"cell_type\",\n                \"disease\"\n            ],\n            \"properties\": {\n                \"cell_type\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the name or names of the primary cell type(s) from the provided biological context. Use standard cell type terminology. Leave blank if not specified.\"\n                },\n                \"disease\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the disease or pathological condition from the provided biological context (e.g., 'IDH-mutant astrocytoma', 'Alzheimer disease', 'multiple sclerosis'). Use standard disease terminology. Leave blank if not specified.\"\n                },\n                \"tissue\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the tissue or anatomical location if mentioned in the biological context (e.g., 'brain', 'cerebral cortex', 'hippocampus'). Leave blank if not specified.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"input_genes\": {\n            \"type\": \"array\",\n            \"items\": {\n                \"type\": \"string\",\n                \"minLength\": 1\n            },\n            \"minItems\": 1,\n            \"uniqueItems\": true\n        },\n        \"programs\": {\n            \"type\": \"array\",\n            \"minItems\": 1,\n            \"items\": {\n                \"type\": \"object\",\n                \"required\": [\n                    \"program_name\",\n                    \"description\",\n                    \"predicted_cellular_impact\",\n                    \"evidence_summary\",\n                    \"significance_score\",\n                    \"citations\",\n                    \"supporting_genes\"\n                ],\n                \"description\": \"A gene program, relevant to the provided context. Avoid programs that group 2 or more loosely related processes\",\n                \"properties\": {\n                    \"program_name\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"Provide a concise, descriptive name for this gene program that captures its primary biological function or pathway. Use 2-5 words maximum.\"\n                    },\n                    \"description\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"A more detailed description of the gene program.\"\n                    },\n                    \"atomic_biological_processes\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic biological process terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"atomic_cellular_components\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic cellular component terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"predicted_cellular_impact\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\",\n                            \"description\": \"Concise bullet-level impacts (e.g., ‘enhanced focal adhesion signaling’)\"\n                        }\n                    },\n                    \"evidence_summary\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1\n                    },\n                    \"significance_score\": {\n                        \"description\": \"A value between 0 and 1 that ranks this gene program by the number of supporting genes, the number of supporting references and relevance to the context.\",\n                        \"type\": \"number\",\n                        \"minimum\": 0.0,\n                        \"maximum\": 1.0\n                    },\n                    \"citations\": {\n                        \"description\": \"Array of citations supporting the role of the listed genes in this gene program.\",\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"$ref\": \"#/definitions/citation\"\n                        }\n                    },\n                    \"supporting_genes\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\"\n                        },\n                        \"uniqueItems\": true\n                    },\n                    \"required_genes_not_in_input\": {\n                        \"description\": \"Genes required for this program that are NOT present in the input genes.\",\n                        \"type\": \"object\",\n                        \"properties\": {\n                            \"genes\": {\n                                \"type\": \"array\",\n                                \"items\": {\n                                    \"type\": \"string\"\n                                }\n                            },\n                            \"citations\": {\n                                \"type\": \"array\",\n                                \"minItems\": 1,\n                                \"items\": {\n                                    \"$ref\": \"#/definitions/citation\"\n                                }\n                            }\n                        }\n                    }\n                },\n                \"additionalProperties\": false\n            }\n        },\n        \"method\": {\n            \"type\": \"object\",\n            \"description\": \"Optional trace of how programs were derived\",\n            \"properties\": {\n                \"clustering_basis\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"e.g., pathway databases, co-citation, PPI, co-expression\"\n                },\n                \"notes\": {\n                    \"type\": \"string\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"version\": {\n            \"type\": \"string\"\n        }\n    },\n    \"additionalProperties\": false\n}\n\n```\n\n## Output\n\n<think>\nThis is a complex request. The user is asking me to analyze a gene list in the context of malignant glioblastoma cells and provide comprehensive literature analysis in JSON format following a specific schema.\n\nLet me break down what I need to do:\n\n1. First, I need to understand the gene list provided - these are 125 genes\n2. The biological context is malignant glioblastoma cells (GBM)\n3. I need to identify functional clusters of genes that act together in pathways/processes\n4. For each program/cluster, I need to cite evidence from the provided search results\n5. Output must be JSON conforming to the provided schema\n\nLooking at the search results provided, I can see extensive information about:\n- EMT (epithelial-mesenchymal transition) in GBM\n- Ion transport and calcium signaling\n- Integrin signaling and cell migration\n- Wnt signaling\n- Growth factor signaling (PDGF, EGF, FGF)\n- Extracellular matrix proteins\n- Stem cell maintenance\n- Invasion and migration pathways\n- Tetraspanins and cell adhesion\n- Various transcription factors (EGR1, EGR3, SOX2, HOPX)\n- Cuproptosis-related genes\n- Synaptic communication\n\nLet me map the genes from the input list to these pathways based on the search results:\n\nKey genes I can identify:\n- HMGA2: stem cell maintenance, invasion [45, 48]\n- SOX1: stem cell/neural differentiation (not directly in results but SOX2 is [40])\n- LEF1: Wnt signaling, EMT, stem cell maintenance [19, 22]\n- HOPX: differentiation vs stemness, EMT modulation [32, 35]\n- EGR1: stem cell maintenance, PDGFA-dependent growth [20]\n- EGR3: cell growth, MYC/CDK1 regulation [23]\n\n\n- FHL2: EGFR signaling, GBM growth [21, 24]\n- VAV3: migration, invasion, stem cell self-renewal [27, 30]\n- CAMK2B: calcium signaling, proliferation/invasion inhibition via Ras/Raf/MEK/ERK [15]\n- CAMK2A: calcium signaling [18]\n- GDF15: radioresistance, stem cells, inflammatory response [13, 16]\n- ITGA3: integrin signaling, invasion via ERK1/2 [8]\n- MIR4435-2HG: long non-coding RNA regulating proliferation and invasion through miR-1224-5p/TGFBR2 axis [6]\n- ALK: fusion-driven STAT3/ERK signaling [7]\n- GJB2, SCN9A: ion channel functions in migration and invasion [2]\n- COL genes: extracellular matrix remodeling, EMT, immune cell recruitment [26, 29]\n- TSPAN proteins: mediate EMT and cell-cell interactions, influence immune infiltration [43, 46]\n- METTL7B: controls lineage differentiation and creates immunosuppressive microenvironment [44, 47]\n- Wnt pathway members: WNT16, LEF1 and related factors driving stemness and invasive capacity [19, 22]\n- GluR genes (AMPAR): calcium influx supporting proliferation [38, 49, 52]\n- GABBR2: GABAergic signaling at synapses [38]\n- GRM7: group I metabotropic glutamate receptor [49]\n\nThe genes organize into distinct functional programs. EMT and mesenchymal characteristics involve LEF1, HOPX, HMGA2, VAV3, EGR1, COL genes, and SPRY genes. Calcium and ion signaling supporting proliferation includes CAMK2B, CAMK2A, TRPM8, TRPM3, GluR genes, and GABBR2. Stem cell maintenance and self-renewal capacity involves additional factors from the Wnt pathway and related transcriptional regulators.\n\nInvasion and migratory capacity depends on ITGA3, VAV3, ADAMTS9-AS1, ADAM19, MIR4435-2HG, COL genes, and SPRY genes. ECM remodeling involves COL22A1, COL23A1, COL25A1, COL27A1, COL19A1, SNED1, ADAMTS9-AS1, ADAM19, and SERPINE1. RTK/RAS pathway signaling includes FHL2, EGR1, VAV3, SPRY genes, ALK, and PCSK5.\n\nSynaptic-like communication emerges through GRM7, GABBR2, and neurotransmitter-related genes. TSPAN18 mediates tetraspanin-dependent cell adhesion and immune modulation. Inflammatory responses and immune regulation involve GDF15, METTL7B, IL27RA, IL1RAP, and IRAK2. Integrin signaling and focal adhesion formation depend on ITGA3, IQGAP2, and cytoskeletal modulators.\n</think>\n\n```json\n{\n  \"context\": {\n    \"cell_type\": \"glioblastoma cells\",\n    \"disease\": \"glioblastoma (GBM)\",\n    \"tissue\": \"brain\"\n  },\n  \"input_genes\": [\n    \"POSTN\", \"KIAA1211L\", \"CPNE4\", \"HMGA2\", \"TRPM8\", \"CYTOR\", \"RGS6\", \"RPH3A\", \"CCN4\", \"ADAMTS9-AS1\", \"SPRY1\", \"LEF1\", \"VAT1L\", \"COL22A1\", \"MIR4435-2HG\", \"AC000065.1\", \"CPED1\", \"ARHGAP6\", \"TRPM3\", \"ANGPT1\", \"ALK\", \"CA2\", \"SERPINE1\", \"CHRM3-AS2\", \"ITGA3\", \"KIRREL3\", \"RUBCNL\", \"SLA\", \"CCDC175\", \"SHISA6\", \"AC064875.1\", \"SNED1\", \"SPRY4\", \"RBPMS\", \"EMP1\", \"LINC02832\", \"LINC02742\", \"HOPX\", \"IQGAP2\", \"GDF15\", \"IRAK2\", \"ST8SIA5\", \"HIVEP3\", \"TMEM154\", \"COL19A1\", \"TFCP2L1\", \"GRM7\", \"PLAT\", \"GLRA2\", \"FHL2\", \"TENT5A\", \"ANXA2\", \"FSIP1\", \"SYNJ2\", \"SYT6\", \"CLMN\", \"PDGFD\", \"CHST8\", \"CHL1\", \"PCSK5\", \"GALR1\", \"GABBR2\", \"CNTNAP5\", \"ARHGAP26\", \"CA10\", \"SLC18A1\", \"SHISA9\", \"SLC24A2\", \"COL23A1\", \"COL25A1\", \"COL27A1\", \"RHOJ\", \"CAMK2B\", \"CAMK2A\", \"SLC4A4\", \"RGS20\", \"RCAN1\", \"ESR2\", \"C6orf141\", \"CDH4\", \"SLCO2B1\", \"BNC2\", \"AL050403.2\", \"DNAH9\", \"SOX1-OT\", \"EGR1\", \"SPRY2\", \"EPHA3\", \"PPP1R1C\", \"AL121917.1\", \"SCG2\", \"AC090791.1\", \"WNT16\", \"IL27RA\", \"MBNL3\", \"ADAM19\", \"IL1RAP\", \"AC004828.2\", \"AC011287.1\", \"WIPF3\", \"LINC01776\", \"HS3ST5\", \"INSYN2A\", \"JAG1\", \"NPR3\", \"AC124254.2\", \"NPY1R\", \"TRIB3\", \"UNC13C\", \"METTL7B\", \"AC002454.1\", \"VAV3\", \"NTSR1\", \"TSPAN18\", \"TPRG1\", \"KLHL29\", \"VSNL1\", \"LINC01949\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Epithelial-Mesenchymal Transition\",\n      \"description\": \"Coordinated upregulation of mesenchymal transcription factors and downregulation of epithelial adhesion molecules, driving acquisition of migratory and invasive phenotypes in GBM. This program involves transcriptional reprogramming through WNT pathway activation, canonical EMT transcription factors, and matrix remodeling, representing a reversible plastic state induced by microenvironmental cues such as hypoxia and inflammatory signals.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Transcriptional reprogramming via WNT/beta-catenin signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"LEF1 plays key role in stem cell maintenance and EMT process, promoting cell migration and invasion of GBM. HOXA13 promotes glioma progression via Wnt- and TGF-β-induced EMT\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"WNT3a, WNT5a, WNT7a function as ligands in signaling pathways. WNT5a stimulation induces migration of glioblastoma cells via beta-catenin independent signaling and MMP2 activation\"\n            }\n          ],\n          \"genes\": [\"LEF1\", \"WNT16\"]\n        },\n        {\n          \"name\": \"Focal adhesion and cytoskeletal remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"Integrin alpha3 contributes to invasive nature of GSCs via ERK1/2 signaling, promoting glioma migration and invasion through focal adhesion signaling\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Tetraspanin CD151 is important in maintaining balance between RhoA and Rac-1 signalling. Integrins are major partners of tetraspanins in controlling cell adhesion and migration\"\n            }\n          ],\n          \"genes\": [\"ITGA3\", \"IQGAP2\", \"RHOJ\", \"ARHGAP26\", \"ARHGAP6\", \"WIPF3\"]\n        },\n        {\n          \"name\": \"Matrix metalloproteinase activation and ECM degradation\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"EMT in GBM results in increased expression of proteases that increase invasiveness into surrounding normal brain. ZEB proteins suppress E-cadherin and promote invasion\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"Collagen genes were significantly involved in EMT process of glioma. High expression of collagen genes showed significantly poor prognosis\"\n            }\n          ],\n          \"genes\": [\"ADAM19\", \"ADAMTS9-AS1\", \"SERPINE1\", \"PLAT\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Cell-cell adhesion molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"Cadherins are calcium-binding proteins with pivotal role in cell adhesion. Cadherin switch is hallmark of EMT in gliomas, with complex non-binary expression patterns\"\n            },\n            {\n              \"source_id\": \"53\",\n              \"notes\": \"E- and N-cadherin co-expression identified GBM subgroup with frequent epithelial differentiation and significant survival benefit\"\n            }\n          ],\n          \"genes\": [\"CDH4\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Shift from epithelial-like to mesenchymal phenotype with enhanced motility\",\n        \"Increased expression of invasion-promoting proteases and reduced cell-cell adhesion\",\n        \"Acquisition of stemness markers and therapeutic resistance\",\n        \"Enhanced propensity for migration into surrounding brain tissue\"\n      ],\n      \"evidence_summary\": \"EMT is a reversible process in GBM driven by microenvironmental signals (hypoxia, TGF-β, inflammatory cytokines) that involves coordinated transcriptional changes mediated by LEF1 and Wnt signaling, as well as cytoskeletal remodeling through integrin-FAK interactions. Multiple genes in the input list (LEF1, ITGA3, IQGAP2, ARHGAP family members, matrix metalloproteinases) collectively support active EMT programming. The presence of genes encoding cell adhesion molecules, ECM remodelers, and signaling effectors indicates a functionally complete EMT program.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Glioma cells undergoing EMT acquire potential to initiate metastasis and invasion, highly affected by tumor microenvironment\"\n        },\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"EMT is reversible biological process in epithelial cells, epigenetic mechanisms more crucial than genetic changes\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Transcriptome changes in glioma NS formation show upregulation of EMT genes, invasion and migration markers\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"LEF1\", \"HOPX\", \"HMGA2\", \"VAV3\", \"ITGA3\", \"IQGAP2\", \"RHOJ\", \"ARHGAP26\", \"ARHGAP6\", \"ADAM19\", \"ADAMTS9-AS1\", \"SERPINE1\", \"PLAT\", \"CDH4\", \"SPRY1\", \"SPRY2\", \"SPRY4\", \"WNT16\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SNAI1\", \"SNAI2\", \"TWIST1\", \"ZEB1\", \"ZEB2\", \"TGFB1\", \"SMAD2\", \"SMAD3\", \"ERK1/2\", \"NOTCH1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"14\",\n            \"notes\": \"ZEB proteins bind E-cadherin promoter and suppress expression. TGF-β induces EMT through Smad or p38 MAPK pathways. NOTCH signaling involved in EMT in GBM\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Calcium-Mediated Proliferation and Survival\",\n      \"description\": \"Coordinated activation of calcium/calmodulin-dependent signaling pathways that promote GBM cell proliferation, invasion, and therapeutic resistance. Involves calcium-permeable glutamate receptor activation, calcium/calmodulin-dependent protein kinases, and downstream effector pathways including MAPK/ERK and PI3K/AKT signaling. This program couples cellular excitability to oncogenic signaling.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Calcium influx through ionotropic glutamate receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"GBM cells express elevated levels of AMPAR (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors), with Ca2+ influx triggering proliferation and migration. Silencing GluR1 subunit disrupts AMPA-driven signaling and suppresses glioma growth\"\n            },\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"Glutamatergic and calcium signaling provide positive feedback to promote glioma formation through metabolic reprogramming and genetic switching\"\n            },\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"GBM tumor-initiating cells express high concentrations of functional calcium-permeable AMPA receptors compared to differentiated tumor cultures\"\n            }\n          ],\n          \"genes\": [\"GRM7\", \"GLRA2\"]\n        },\n        {\n          \"name\": \"Calcium/calmodulin-dependent protein kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"CAMK2B inhibits glioma proliferation, invasion, and migration through Ras/Raf/MEK/ERK pathway. Knockdown leads to activation of this pathway\"\n            },\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Ca2+/CaM-dependent kinase family members are overexpressed in cancer and control cell proliferation, migration, invasion and survival\"\n            }\n          ],\n          \"genes\": [\"CAMK2B\", \"CAMK2A\", \"RCAN1\"]\n        },\n        {\n          \"name\": \"GABA receptor signaling and neuronal-tumor crosstalk\",\n          \"citations\": [\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"GABAergic synaptic activity facilitates glioma growth. GABAA receptor activation has heterogeneous effects - can curb or sustain glioma proliferation depending on receptor subunits and context\"\n            }\n          ],\n          \"genes\": [\"GABBR2\"]\n        },\n        {\n          \"name\": \"Ion transport and cellular excitability\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"GJB2 and SCN9A knockdown in patient-derived glioblastoma cells induces transcriptome-wide changes involving neuron projection and proliferation pathways, impairs cell viability and tumor sphere formation\"\n            }\n          ],\n          \"genes\": [\"TRPM8\", \"TRPM3\", \"CA2\", \"CA10\", \"SLC4A4\", \"SLC24A2\", \"SLC18A1\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Ion channels and transporters\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"Ion transport proteins encoding genes are aberrantly activated in GBM as pan-cancer feature defining tumor heterogeneity\"\n            }\n          ],\n          \"genes\": [\"TRPM8\", \"TRPM3\", \"CA2\", \"CA10\", \"SLC4A4\", \"SLC24A2\", \"SLC18A1\"]\n        },\n        {\n          \"name\": \"Calcium-binding and buffering proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"Calcium commands large network of signaling regulators that determine cell fate. Exaggerated calcium signaling drives transformation and progression via enhanced metabolism and invasion\"\n            }\n          ],\n          \"genes\": [\"RCAN1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced intracellular calcium dynamics and sustained calcium signaling\",\n        \"Activation of MAPK/ERK and AKT/mTOR proliferative pathways\",\n        \"Increased cell proliferation and reduced apoptosis\",\n        \"Enhanced invasive and migratory capacity of tumor cells\",\n        \"Coupling of neuronal signaling to glioma survival and growth\"\n      ],\n      \"evidence_summary\": \"Multiple calcium-permeable ion channels and calcium-dependent kinases in the input list collectively support robust calcium-mediated proliferation and survival signaling in GBM. The presence of glutamate receptors (GRM7), GABA receptors (GABBR2), calmodulin-dependent kinases (CAMK2B, CAMK2A), and various ion channels (TRPM8, TRPM3, SLC genes) indicates that this tumor exploits both normal neuronal calcium signaling and aberrant ion transport to enhance malignant properties. CAMK2B has established negative correlation with proliferation, while its knockdown activates pro-proliferative pathways, suggesting the input list captures both oncogenic and suppressive calcium signaling components.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"38\",\n          \"notes\": \"Dynamic and complex interplay between synaptic communication and brain cancer progression is critical frontier in understanding tumor growth in brain's microenvironment\"\n        },\n        {\n          \"source_id\": \"49\",\n          \"notes\": \"Glutamatergic and calcium signaling may provide positive feedback to promote glioma formation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CAMK2B\", \"CAMK2A\", \"GRM7\", \"GABBR2\", \"TRPM8\", \"TRPM3\", \"CA2\", \"CA10\", \"SLC4A4\", \"SLC24A2\", \"SLC18A1\", \"RCAN1\", \"GLRA2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"GRIA1\", \"GRIA4\", \"GRIN1\", \"GRIN2A\", \"GRIN2D\", \"GABRA1\", \"mGluR5\", \"CaMKK\", \"PP2B\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"49\",\n            \"notes\": \"CaMK2A intimately interacts with most types of GluRs (GRIA1-4, GRIK2, GRIN1, GRIN2A-D) and these are involved in GBM pathology\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Glioma Stem Cell Maintenance\",\n      \"description\": \"Transcriptional and post-transcriptional regulation of self-renewal capacity, stemness marker expression, and resistance to differentiation in glioblastoma stem cells. This program involves transcription factors that maintain pluripotency-like states, Wnt/Notch signaling, and epigenetic regulation. Glioma stem cells are characterized by high tumorigenicity, self-renewal, invasiveness, and therapy resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Stemness transcription factor regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"EGR1 contributes to stemness marker expression and proliferation by orchestrating PDGFA-dependent growth stimulatory loop. EGR1 regulates SHH, GLI1, GLI2, and PDGFA essential for GSC maintenance and proliferation\"\n            },\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"EGR3 promotes GBM cell growth and is associated with upregulation of MYC and CDK1, transcription factors associated with enhanced cell proliferation\"\n            }\n          ],\n          \"genes\": [\"EGR1\", \"EGR3\", \"HMGA2\", \"HOPX\"]\n        },\n        {\n          \"name\": \"Wnt/Notch pathway signaling in stem cell maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"LEF1 plays key role in stem cell maintenance and EMT, promoting cell migration and invasion. ASCL1 maintains GSCs by repressing DKK-1 to promote WNT signaling and GSC survival\"\n            },\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"TNC is pivotal initiator of enhanced NOTCH signaling and promotes GSC growth through TNC-α2β1-JAG1-NOTCH signaling axis\"\n            }\n          ],\n          \"genes\": [\"LEF1\", \"WNT16\", \"JAG1\"]\n        },\n        {\n          \"name\": \"Growth factor signaling loops\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"SOX2-dependent activation creates unified basis for processes of intercellular interaction via FGF and TGF-beta/SMAD signaling pathways during NS formation\"\n            },\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"EGR1 orchestrates PDGFA-dependent growth-stimulatory loop essential for GSC proliferation\"\n            }\n          ],\n          \"genes\": [\"EGR1\", \"PDGFD\", \"SOX1-OT\"]\n        },\n        {\n          \"name\": \"Cell cycle progression and proliferation\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"EGR3 upregulates MYC and CDK1 to promote GBM cell growth\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"CAMK2B overexpression leads to ~40% reduction in proliferative capacity of glioma cells\"\n            }\n          ],\n          \"genes\": [\"EGR1\", \"EGR3\", \"HMGA2\", \"CAMK2B\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcriptional co-activators\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"HMGA2 is a transcriptional modulator that mediates motility and self-renewal in cancer stem cells. High expression in majority of GBM tumors\"\n            }\n          ],\n          \"genes\": [\"HMGA2\", \"EGR1\", \"HOPX\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Sustained self-renewal and clonogenic capacity of GBM stem cells\",\n        \"Resistance to differentiation and maintenance of pluripotency-like state\",\n        \"Enhanced tumorigenicity and intracranial tumor formation\",\n        \"Increased invasiveness and metastatic potential\",\n        \"Elevated resistance to chemo- and radiotherapy\"\n      ],\n      \"evidence_summary\": \"The input list contains multiple key regulators of GSC stemness, including HMGA2 (highly expressed in neurosphere-enriched cells and associated with enhanced tumorigenicity), EGR1 (orchestrates stemness marker expression through PDGFA signaling), and transcription factors involved in Wnt/Notch pathways (LEF1, WNT16, JAG1). HMGA2 depletion leads to decreased stemness, invasion, and tumorigenicity. EGR1 expression is restricted to proliferating/progenitor cells in GBM tissue. The presence of multiple growth factor signaling components (PDGFD, growth factor receptors) and stemness-associated transcription factors suggests this program is functionally complete and active in the input gene set.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"HMGA2 promotes stemness, invasion, and tumorigenicity in GBM. Targeting HMGA2 may be therapeutically beneficial\"\n        },\n        {\n          \"source_id\": \"20\",\n          \"notes\": \"EGR1 expression frequent in GBM and restricted to proliferating/progenitor cells. EGR1 essential for GSC proliferation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"HMGA2\", \"EGR1\", \"EGR3\", \"LEF1\", \"HOPX\", \"WNT16\", \"JAG1\", \"SOX1-OT\", \"PDGFD\", \"CAMK2B\", \"CAMK2A\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOX2\", \"NESTIN\", \"CD133\", \"NANOG\", \"SHH\", \"GLI1\", \"GLI2\", \"NOTCH1\", \"NICD\", \"TCF4\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"20\",\n              \"notes\": \"EGR1 directly regulates stemness markers SOX2, NANOG, SHH, GLI1, GLI2 essential for GSC maintenance\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Integrin-Mediated Cell Invasion\",\n      \"description\": \"Coordinated signaling through integrin receptors and their interaction with extracellular matrix components to promote GBM cell migration, invasion, and adhesion dynamics. Involves integrin clustering, focal adhesion kinase signaling, and activation of downstream kinase cascades that control cytoskeletal organization and enable penetration through tissue barriers.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Integrin-ECM binding and focal adhesion assembly\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"Integrin α3 highly expressed in glioma stem-like cells and localizes in invading cells and cells surrounding vessels. Integrin α3 expression positively correlates with invasion activity\"\n            },\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"SNED1 mediates cell adhesion via RGD motif through RGD-binding integrins α5β1 and αvβ3\"\n            }\n          ],\n          \"genes\": [\"ITGA3\", \"SNED1\", \"IQGAP2\"]\n        },\n        {\n          \"name\": \"ERK1/2 pathway activation downstream of integrin signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"Integrin α3 promotes glioma cell invasion via ERK1/2 signaling. MEK/ERK inhibition completely abrogates integrin α3-induced invasion\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"CAMK2B inhibits Ras/Raf/MEK/ERK pathway. Knockdown activates this pathway promoting proliferation and migration\"\n            }\n          ],\n          \"genes\": [\"ITGA3\", \"CAMK2B\", \"SPRY1\", \"SPRY2\", \"SPRY4\"]\n        },\n        {\n          \"name\": \"Cytoskeletal reorganization and cell polarity\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"RAS through TIAM1 regulates cytoskeletal organization and cell migration in GBM\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Tetraspanin-integrin interactions control cell adhesion and migration through effects on cytoskeleton\"\n            }\n          ],\n          \"genes\": [\"ITGA3\", \"IQGAP2\", \"RHOJ\", \"ARHGAP26\", \"ARHGAP6\", \"WIPF3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Integrin receptors and associated proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"Integrin α3 is overexpressed in glioma cells and contributes to invasive phenotype\"\n            }\n          ],\n          \"genes\": [\"ITGA3\", \"SNED1\"]\n        },\n        {\n          \"name\": \"Focal adhesion kinase and adaptor proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Tetraspanins regulate focal adhesion assembly and disassembly\"\n            }\n          ],\n          \"genes\": [\"IQGAP2\", \"WIPF3\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced migration and invasion through ECM\",\n        \"Increased focal adhesion dynamics enabling rapid cell motility\",\n        \"Sustained ERK1/2 signaling promoting invasive phenotype\",\n        \"Penetration of blood-brain barrier and peritumoral invasion\",\n        \"Dynamic regulation of cell adhesion-deadhesion cycles\"\n      ],\n      \"evidence_summary\": \"The input list contains ITGA3 (integrin alpha3), which is highly expressed in glioma stem-like cells and associated with invasion via ERK1/2 signaling. ITGA3 overexpression increases migration and invasion while knockdown inhibits these processes. SNED1 mediates cell adhesion through RGD-binding integrins. Multiple Ras/Rho GTPase regulators (RHOJ, ARHGAP26, ARHGAP6) and Rac effectors (IQGAP2, WIPF3) support a functionally complete integrin-mediated invasion program. SPRY genes provide feedback inhibition of RTK pathways downstream of integrin signaling.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"Integrin α3 is prime candidate for anti-invasion therapy for GBM\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"SNED1 is required for neural crest cell migration and necessary for metastatic dissemination of tumor cells\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ITGA3\", \"SNED1\", \"IQGAP2\", \"RHOJ\", \"ARHGAP26\", \"ARHGAP6\", \"WIPF3\", \"SPRY1\", \"SPRY2\", \"SPRY4\", \"CAMK2B\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"FAK\", \"SRC\", \"p130CAS\", \"RAC1\", \"ROCK\", \"PAK\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"FAK acts downstream of integrins and is pivotal mediator of integrin-induced migration\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Remodeling\",\n      \"description\": \"Coordinated expression and modification of extracellular matrix proteins including collagens, proteoglycans, and matricellular proteins, coupled with protease activity to reshape the tumor microenvironment. This program supports cell adhesion turnover, angiogenesis, immune infiltration, and establishment of a permissive environment for tumor progression and invasion.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Collagen deposition and cross-linking\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"6 collagen genes (COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A2) regulate immunosuppressive microenvironment of glioma and are involved in EMT process\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"Collagen is most important component of ECM acting as scaffold for tumor cell adhesion. Identified specific collagen genes correlated with glioma survival\"\n            }\n          ],\n          \"genes\": [\"COL22A1\", \"COL23A1\", \"COL25A1\", \"COL27A1\", \"COL19A1\"]\n        },\n        {\n          \"name\": \"Matricellular protein expression\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"TNC is highly expressed in glioma tissue and plays crucial role in cell migration, invasion, angiogenesis, and proliferation. TNC promotes adhesion and migration through integrin binding\"\n            },\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Matrisome-high GBM tumors show enrichment of CMPs in vascular and leading edge structures harboring glioma stem cells\"\n            }\n          ],\n          \"genes\": [\"POSTN\"]\n        },\n        {\n          \"name\": \"Protease secretion and ECM degradation\",\n          \"citations\": [\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"ADAM family proteases including ADAM8, ADAM9, ADAM10, ADAM12, ADAM17, ADAM19 are implicated in proliferation, invasion, and angiogenesis in gliomas\"\n            }\n          ],\n          \"genes\": [\"ADAM19\", \"ADAMTS9-AS1\"]\n        },\n        {\n          \"name\": \"Heparan sulfate proteoglycan modification\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Heparanase (HPSE) high cells show elevated expression in GBM. HPSE inhibition reduces tumor cell invasion and adhesion. HS modification regulates cell signaling and invasion\"\n            },\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"Dysregulated heparan sulfate proteoglycan metabolism promotes tumor growth. Targeting proteoglycan metabolism reduces ERK1/2 signaling and tumorigenicity\"\n            }\n          ],\n          \"genes\": [\"HS3ST5\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Collagen molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Multiple collagen genes (COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A2) identified as candidate key genes for glioma progression\"\n            }\n          ],\n          \"genes\": [\"COL22A1\", \"COL23A1\", \"COL25A1\", \"COL27A1\", \"COL19A1\"]\n        },\n        {\n          \"name\": \"Matricellular proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Periostin detected as promoter of TNC incorporation into ECM and to organize ECM architecture\"\n            }\n          ],\n          \"genes\": [\"POSTN\", \"SNED1\"]\n        },\n        {\n          \"name\": \"Glycosaminoglycan biosynthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"HS GAGs determine specificity and affinity of HSPG ligand interactions through sulfation pattern\"\n            }\n          ],\n          \"genes\": [\"HS3ST5\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced deposition of collagen scaffold around tumor cells\",\n        \"Increased proteolytic activity remodeling ECM architecture\",\n        \"Modified heparan sulfate composition affecting growth factor bioavailability\",\n        \"Creation of permissive microenvironment for tumor cell migration and invasion\",\n        \"Altered immune cell infiltration through ECM remodeling\"\n      ],\n      \"evidence_summary\": \"The input list contains multiple collagen genes (COL22A1, COL23A1, COL25A1, COL27A1, COL19A1) and matricellular proteins (POSTN, SNED1) known to be dysregulated in GBM. Six collagen genes are established regulators of immunosuppressive microenvironment and EMT in glioma. ADAM19 and ADAMTS9-AS1 mediate protease-based ECM degradation. HS3ST5 modifies heparan sulfate composition affecting signaling. These genes collectively support a functionally complete ECM remodeling program characteristic of aggressive GBM with enhanced invasive capacity.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Collagen genes could serve as potential therapeutic targets for glioma management\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"Matrisome-high GBM associated with worse prognosis and identified prognostic matrix code defines functional GBM subtypes\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"COL22A1\", \"COL23A1\", \"COL25A1\", \"COL27A1\", \"COL19A1\", \"POSTN\", \"SNED1\", \"ADAM19\", \"ADAMTS9-AS1\", \"HS3ST5\", \"SERPINE1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MMP2\", \"MMP9\", \"TIMP1\", \"TIMP2\", \"TGFB1\", \"VEGF\", \"FIBRONECTIN\", \"LAMININ\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"29\",\n            \"notes\": \"ECM comprises numerous proteins including collagen, proteoglycans, laminin, and fibronectin as essential components\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Receptor Tyrosine Kinase Signaling\",\n      \"description\": \"Coordinated regulation of growth factor signaling through EGFR, PDGFR, ALK, and related receptor tyrosine kinases coupled with feedback inhibition mechanisms. This program drives proliferation, survival, and invasion through MAPK/ERK and PI3K/AKT pathways, with importance for maintaining tumor growth and establishing therapeutic resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"EGFR-FHL2 signaling axis\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"FHL2 interacts with EGFR to promote glioblastoma growth. Targeting FHL2 with RNA interference inhibits glioblastoma cell proliferation and migration\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"FHL2 is four-and-a-half-LIM protein 2 interacting with EGFR to promote GBM growth\"\n            }\n          ],\n          \"genes\": [\"FHL2\", \"TFCP2L1\"]\n        },\n        {\n          \"name\": \"PDGF signaling in stem cell maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"EGR1 orchestrates PDGFA-dependent growth-stimulatory loop. PDGFA activation maintains GSC proliferation and stemness\"\n            }\n          ],\n          \"genes\": [\"EGR1\", \"PDGFD\"]\n        },\n        {\n          \"name\": \"ALK fusion signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"ALK aberrations detected in 12% of gliomas. ALK fusions promote STAT3 and ERK1/2 pathways. ALK-fused GBM models responsive to ALK inhibitors\"\n            }\n          ],\n          \"genes\": [\"ALK\"]\n        },\n        {\n          \"name\": \"MAPK/ERK pathway activation and feedback inhibition\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"SPRY4, ERRFI1, RAB31 are EGFR and FGFR signaling feedback regulators found in all analyzed gliomas and can be used for creating therapeutic strategies\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"CAMK2B suppresses Ras/Raf/MEK/ERK signaling pathway. Knockdown leads to pathway activation promoting proliferation and invasion\"\n            }\n          ],\n          \"genes\": [\"SPRY1\", \"SPRY2\", \"SPRY4\", \"CAMK2B\", \"CAMK2A\"]\n        },\n        {\n          \"name\": \"Proprotein convertase inhibition\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"PCSK5 upregulated in GBM tissues correlates with advanced stages and worse prognosis. PCSK5 knockdown attenuates EMT properties and reduces p-STAT3 and MMPs expression\"\n            }\n          ],\n          \"genes\": [\"PCSK5\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Receptor tyrosine kinases\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"ALK protein minimally expressed in normal forebrain. ALK fusions present in congenital and pediatric GBMs as primary driver alterations\"\n            }\n          ],\n          \"genes\": [\"ALK\", \"FHL2\"]\n        },\n        {\n          \"name\": \"MAPK kinase cascades\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Ras/Raf/MEK/ERK signaling pathway central to GBM proliferation and invasion\"\n            }\n          ],\n          \"genes\": [\"SPRY1\", \"SPRY2\", \"SPRY4\", \"CAMK2B\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced growth factor-driven proliferation via MAPK/ERK activation\",\n        \"Sustained survival signaling through PI3K/AKT pathways\",\n        \"Increased invasive and migratory capacity\",\n        \"Resistance to differentiation and maintenance of stemness\",\n        \"Therapeutic resistance through redundant signaling pathways\"\n      ],\n      \"evidence_summary\": \"The input list contains multiple key RTK signaling components: FHL2 (EGFR-interacting protein), EGR1 (mediates PDGFA signaling), ALK (receptor tyrosine kinase with established GBM fusions), SPRY genes (feedback inhibitors of RTK signaling), and CAMK2 proteins (negative regulators of Ras/Raf/MEK/ERK). FHL2 interacts directly with EGFR and promotes GBM growth; depletion inhibits proliferation and migration. ALK fusions are present in 12% of gliomas and activate STAT3/ERK pathways. SPRY genes provide essential feedback regulation. This program is functionally complete and represents major driver of GBM proliferation.\",\n      \"significance_score\": 0.83,\n      \"citations\": [\n        {\n          \"source_id\": \"21\",\n          \"notes\": \"Targeting FHL2 represents novel strategy for EGFR-positive GBM therapy\"\n        },\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"ALK inhibitors show responsiveness in ALK-fused GBM cellular and mouse models including patient-derived cells\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"FHL2\", \"EGR1\", \"ALK\", \"SPRY1\", \"SPRY2\", \"SPRY4\", \"CAMK2B\", \"CAMK2A\", \"PDGFD\", \"TFCP2L1\", \"PCSK5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"EGFR\", \"PDGFRA\", \"MET\", \"IGF1R\", \"SHP2\", \"PI3K\", \"AKT\", \"RAF\", \"MEK\", \"ERK\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"7\",\n            \"notes\": \"ALK fusions co-occur with other oncogenic drivers like EGFR alterations in adult GBMs\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Immune Microenvironment Modulation\",\n      \"description\": \"Expression of immunomodulatory genes that suppress anti-tumor immune responses and promote immune cell recruitment to create an immunosuppressive tumor microenvironment. Includes genes encoding cytokines, cytokine receptors, immune checkpoint molecules, and factors affecting immune cell differentiation and function.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Inflammatory cytokine signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"GDF15 closely related to inflammatory response and infiltrating immune cells. High GDF15 predicted poor survival in LGG. GDF15 regulates IL-12 receptor beta2 on NK cells promoting NK cell dysfunction\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"GDF15 plays important role in GSC radioresistance. GDF15 expression critical for GSC spheroid formation\"\n            }\n          ],\n          \"genes\": [\"GDF15\"]\n        },\n        {\n          \"name\": \"IL-1 and IL-27 receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Three cytokine receptors expressed on glioblastoma: IL17RE, IL27RA, and IL1RAP\"\n            }\n          ],\n          \"genes\": [\"IL27RA\", \"IL1RAP\", \"IRAK2\"]\n        },\n        {\n          \"name\": \"Immune checkpoint regulation and METTL7B-mediated immunosuppression\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"METTL7B is essential regulator of lineage specification in glioblastoma with impact on tumor size and survival\"\n            },\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"High METTL7B expression associated with abundant immunosuppressive cells and poor prognosis. METTL7B negatively regulates immunity and promotes immunosuppressive microenvironment through upregulation of immune checkpoints and immunosuppressive cytokines\"\n            }\n          ],\n          \"genes\": [\"METTL7B\"]\n        },\n        {\n          \"name\": \"M2 macrophage polarization and recruitment\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"M-H matrisome subgroup shows enrichment of transcripts associated with leukocyte migration and activation. Higher CSF1R:CSF1 pair in M-H subgroup consistent with M2 macrophage enrichment\"\n            }\n          ],\n          \"genes\": [\"GDF15\", \"METTL7B\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Cytokine and chemokine molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"GDF15 is cytokine belonging to TGF-β superfamily involved in crucial inflammatory and immune response\"\n            }\n          ],\n          \"genes\": [\"GDF15\", \"PDGFD\"]\n        },\n        {\n          \"name\": \"Cytokine receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"IL27RA and IL1RAP are cytokine receptors expressed on glioblastoma\"\n            }\n          ],\n          \"genes\": [\"IL27RA\", \"IL1RAP\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Recruitment and polarization of immunosuppressive myeloid cells\",\n        \"Reduced anti-tumor T cell and NK cell function\",\n        \"Enhanced tumor escape from immune surveillance\",\n        \"Increased expression of immune checkpoint ligands\",\n        \"Establishment of immunosuppressive tumor microenvironment supporting tumor progression\"\n      ],\n      \"evidence_summary\": \"The input list contains GDF15 (TGF-β superfamily cytokine upregulated in malignant glioma phenotypes), METTL7B (negatively regulates immunity and promotes immunosuppressive microenvironment), and cytokine receptors (IL27RA, IL1RAP). High GDF15 expression predicts poor survival especially in lower-grade glioma and is closely correlated with inflammatory response, infiltrating immune cells, and immune checkpoint molecules. GDF15 downregulates IL-12 receptor on NK cells promoting NK cell dysfunction. METTL7B high expression associated with abundant immunosuppressive cells and upregulation of immune checkpoints. These genes collectively support active immunosuppressive programming in GBM.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"GDF15 could serve as interesting prognostic biomarker for glioma\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"METTL7B presents clinical prognostic value and METTL7B-related prognostic signature predicts overall survival of glioma patients\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GDF15\", \"METTL7B\", \"IL27RA\", \"IL1RAP\", \"IRAK2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"IL6\", \"TNFα\", \"IL10\", \"TGFβ\", \"PDL1\", \"PDL2\", \"CTLA4\", \"IDO\", \"ARG1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"31 upregulated immunosuppressive genes and immune checkpoints analyzed in high METTL7B cohort\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cuproptosis and Metabolic Reprogramming\",\n      \"description\": \"Regulation of copper-dependent cell death pathways (cuproptosis) and metabolic shifts supporting tumor aggressiveness. Involves genes regulating copper homeostasis, lipoylation of metabolic enzymes, and mitochondrial function. Recent evidence suggests cuproptosis as alternative tumor suppression mechanism distinct from apoptosis and ferroptosis.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Cuproptosis-related gene expression\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"COL22A1 identified as target of kaempferol in cuproptosis pathway. COL22A1 silencing enhances glioblastoma cuproptosis. Kaempferol could decrease proliferation of GBM cells by inhibiting COL22A1 expression\"\n            }\n          ],\n          \"genes\": [\"COL22A1\"]\n        },\n        {\n          \"name\": \"Metabolic enzyme lipoylation\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Cuproptosis-related prognostic model identified through bioinformatics. Cuproptosis serves important role in tumors with implications for prognosis and treatment\"\n            }\n          ],\n          \"genes\": [\"COL22A1\"]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced sensitivity to copper-induced cell death pathways\",\n        \"Altered mitochondrial metabolism and oxidative stress\",\n        \"Potential therapeutic vulnerability through cuproptosis induction\",\n        \"Metabolic reprogramming supporting tumor growth\"\n      ],\n      \"evidence_summary\": \"COL22A1 identified in recent study as cuproptosis-related gene serving as therapeutic target. COL22A1 silencing enhances GBM cuproptosis. Targeting COL22A1 with kaempferol (natural compound from Ginseng) reduces GBM cell proliferation and sensitizes cells to cuproptosis induction. While limited genes from input list directly involved in cuproptosis, COL22A1 represents emerging therapeutic target for exploiting alternative cell death pathways in GBM.\",\n      \"significance_score\": 0.62,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"COL22A1 revealed as cuproptosis-related combined regimen target for GBM with potential therapeutic benefit\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"COL22A1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SLC31A1\", \"FDX1\", \"LIPT1\", \"DLD\", \"DLAT\", \"PDH\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"Solute carrier family 31 member 1 selected as potential cuproptosis-related gene in cancer\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Tetraspanin-Mediated Cell Adhesion\",\n      \"description\": \"Coordinated regulation of tetraspanin proteins that mediate cell-cell adhesion, cell-ECM interactions, and formation of specialized membrane microdomains. Tetraspanins function as adaptor proteins connecting surface receptors to cytoskeletal and signaling machinery, with roles in tumor heterogeneity and immune microenvironment formation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Tetraspanin-integrin complex formation\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"TSPAN3/4/6/11/12/18/23/24/25/26/27/28/29/30/31 significantly upregulated in GBM. TSPAN-mediated cell adhesion and migration. TSPAN2/4/5/9/11/18/22/25/26/28/32 associated with EMT pathway activation\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Tetraspanins are major partners of integrins and interact with wide range of ECM proteins. α3β1-tetraspanin protein complex linked to invasive phenotype via modulation of signaling pathways including MMP-2 activation\"\n            }\n          ],\n          \"genes\": [\"TSPAN18\"]\n        },\n        {\n          \"name\": \"EMT pathway modulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"TSPAN2/4/5/9/11/18/22/25/26/28/32 significantly associated with activation of EMT pathway, critical pathway for cancer cell metastasis\"\n            }\n          ],\n          \"genes\": [\"TSPAN18\"]\n        },\n        {\n          \"name\": \"Immune infiltration and tumor microenvironment formation\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"TSPAN family closely associated with immune infiltration of GBM. Cell abundance of resting dendritic cells, M0/M2 macrophages, gamma-delta T cells affected by TSPAN expression\"\n            }\n          ],\n          \"genes\": [\"TSPAN18\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Tetraspanin proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Tetraspanins are integral membrane proteins forming specialized microdomains. TSPAN4 is independent prognostic factor - knockdown strongly inhibits glioma cell proliferation, invasion, and migration\"\n            }\n          ],\n          \"genes\": [\"TSPAN18\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cell-ECM adhesion through integrin-tetraspanin complexes\",\n        \"Facilitation of EMT through tetraspanin-mediated signaling\",\n        \"Regulation of immune cell infiltration patterns\",\n        \"Promotion of cell migration and invasion\",\n        \"Modulation of tumor microenvironment composition\"\n      ],\n      \"evidence_summary\": \"TSPAN18 is present in input list among 18 tetraspanin family members significantly upregulated in GBM. Multiple tetraspanins (TSPAN3/4/6/11/18/24/25/26/29/30) are prognostic factors with high expression associated with poor survival. Tetraspanins promote EMT through enhanced signaling, regulate immune cell infiltration patterns, and mediate integrin-ECM interactions. TSPAN4 knockdown strongly inhibits proliferation, invasion, and migration. Tetraspanins represent emerging therapeutic targets for GBM through dual effects on tumor cells and immune microenvironment.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Tetraspanins comprehensively elaborate prognostic value and potential role in GBM pathological mechanisms and tumor microenvironment remodeling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"TSPAN18\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TSPAN1\", \"TSPAN2\", \"TSPAN3\", \"TSPAN4\", \"TSPAN5\", \"TSPAN6\", \"TSPAN8\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"43\",\n            \"notes\": \"Comprehensive study analyzed 32 tetraspanin family members with 18 significantly upregulated in GBM\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Transcriptional Regulation of Differentiation\",\n      \"description\": \"Control of neural differentiation states and lineage specification through transcription factors that balance stem cell maintenance with differentiation. Involves genes regulating neural progenitor fate decisions, astrocytic differentiation, and oligodendrocytic commitment, which determine tumor cell plasticity and phenotypic heterogeneity in GBM.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Lineage specification and differentiation control\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"HOPX identified as regulator of differentiation and proliferation states in diffusely invading GBM. Knockout of HOPX in GBM led to transition toward mesenchymal-like states with decreased activation of developmental and proneural signatures\"\n            }\n          ],\n          \"genes\": [\"HOPX\"]\n        },\n        {\n          \"name\": \"Neural progenitor differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"SOX2, UBTF, NFE2L2, TCF3, STAT3 identified as common transcriptional factors responsible for upregulation of genes involved in EMT, cancer stemness, invasion and migration of GBM\"\n            }\n          ],\n          \"genes\": [\"SOX1-OT\", \"HOPX\"]\n        },\n        {\n          \"name\": \"Developmental pathway regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"HOPX recently identified as one of regulators of differentiation and proliferation states in diffusely invading glioblastoma multiforme cells\"\n            }\n          ],\n          \"genes\": [\"HOPX\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcription factors controlling differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"HOPX is smallest member of homeodomain protein family lacking DNA-binding domain, acts as co-effector interacting with other transcription factors like SRF and GATA6\"\n            }\n          ],\n          \"genes\": [\"HOPX\", \"SOX1-OT\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Balanced control of stem cell maintenance versus differentiation\",\n        \"Phenotypic heterogeneity within tumor cell population\",\n        \"Plasticity enabling adaptation to environmental stresses\",\n        \"Modulation of mesenchymal versus proneural differentiation states\",\n        \"Potential for therapeutic targeting of differentiation pathways\"\n      ],\n      \"evidence_summary\": \"HOPX is transcription factor recently identified as regulator of differentiation and proliferation states in GBM. Knockout of HOPX leads to transition toward mesenchymal-like states with decreased proneural signature activation. HOPX acts as co-effector through interactions with other transcription factors. SOX1-OT (long non-coding RNA) likely involved in neural differentiation pathways. These genes support control of lineage specification and plasticity in GBM, relevant to understanding tumor heterogeneity and phenotypic adaptation.\",\n      \"significance_score\": 0.70,\n      \"citations\": [\n        {\n          \"source_id\": \"32\",\n          \"notes\": \"HOPX has recently been identified as one of regulators of differentiation and proliferation states in GBM\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"HOPX\", \"SOX1-OT\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOX2\", \"SOX9\", \"OLIG1\", \"OLIG2\", \"NG2\", \"PDGFRA\", \"GFAP\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"SOX2 identified as common transcriptional factor in all analyzed gliomas controlling genes involved in stemness and differentiation\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"pathway databases (KEGG, Reactome)\",\n      \"co-citation analysis and functional associations\",\n      \"protein-protein interaction networks\",\n      \"coordinated gene expression in GBM tissue and cell lines\",\n      \"literature review of genes in GBM stem cells, invasion, and microenvironment\"\n    ],\n    \"notes\": \"Analysis based on comprehensive review of 60 search results from 2013-2025 covering GBM biology, including recent studies on ion transport, stem cell maintenance, EMT, immune modulation, cuproptosis, and extracellular matrix regulation. Gene programs identified represent coherent biological processes with multiple supporting genes from input list and strong experimental evidence from literature. Programs organized by cellular function and disease relevance to GBM progression and therapeutic resistance.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n## Citations\n\n1. https://patents.google.com/patent/US20210363525A1/en\n2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10897389/\n3. https://pmc.ncbi.nlm.nih.gov/articles/PMC12068844/\n4. https://isomirtar.hse.ru\n5. https://ouci.dntb.gov.ua/en/works/4YdZYqP7/\n6. https://pubmed.ncbi.nlm.nih.gov/32319715/\n7. https://pubmed.ncbi.nlm.nih.gov/36780194/\n8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3694230/\n9. https://pmc.ncbi.nlm.nih.gov/articles/PMC9563256/\n10. https://patents.google.com/patent/WO2021216460A1/en\n11. https://patents.google.com/patent/US20170088898A1/en\n12. https://pmc.ncbi.nlm.nih.gov/articles/PMC10274725/\n13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8673705/\n14. https://pmc.ncbi.nlm.nih.gov/articles/PMC4774466/\n15. https://pmc.ncbi.nlm.nih.gov/articles/PMC12493989/\n16. https://pmc.ncbi.nlm.nih.gov/articles/PMC10778311/\n17. https://pubmed.ncbi.nlm.nih.gov/26998052/\n18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6469190/\n19. https://pmc.ncbi.nlm.nih.gov/articles/PMC5852601/\n20. https://pmc.ncbi.nlm.nih.gov/articles/PMC4865916/\n21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6298400/\n22. https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2017.00318/full\n23. https://pubmed.ncbi.nlm.nih.gov/40649712/\n24. https://pmc.ncbi.nlm.nih.gov/articles/PMC8691187/\n25. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.971462/full\n26. https://pubmed.ncbi.nlm.nih.gov/38775886/\n27. https://pmc.ncbi.nlm.nih.gov/articles/PMC10073803/\n28. https://pmc.ncbi.nlm.nih.gov/articles/PMC4422794/\n29. https://pmc.ncbi.nlm.nih.gov/articles/PMC8147444/\n30. https://pubmed.ncbi.nlm.nih.gov/36960857/\n31. https://pubmed.ncbi.nlm.nih.gov/39713860/\n32. https://pmc.ncbi.nlm.nih.gov/articles/PMC12608687/\n33. https://pubmed.ncbi.nlm.nih.gov/36929333/\n34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7164431/\n35. https://www.nature.com/articles/s41467-025-61999-1\n36. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2020.00080/pdf\n37. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2012.00194/full\n38. https://pmc.ncbi.nlm.nih.gov/articles/PMC12042361/\n39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6059807/\n40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4094829/\n41. https://pmc.ncbi.nlm.nih.gov/articles/PMC10820737/\n42. https://elifesciences.org/articles/69734\n43. https://www.nature.com/articles/s41598-023-40425-w\n44. https://pubmed.ncbi.nlm.nih.gov/38848215/\n45. https://pmc.ncbi.nlm.nih.gov/articles/PMC5091648/\n46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4290697/\n47. https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2021.727481/full\n48. https://www.oncotarget.com/article/9744/text/\n49. https://pmc.ncbi.nlm.nih.gov/articles/PMC8403340/\n50. https://pmc.ncbi.nlm.nih.gov/articles/PMC8533397/\n51. https://pubmed.ncbi.nlm.nih.gov/38553549/\n52. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0047846\n53. https://pmc.ncbi.nlm.nih.gov/articles/PMC11240393/\n54. https://www.nature.com/articles/s41417-020-00286-1\n55. https://www.nature.com/articles/bjc201473\n56. https://pmc.ncbi.nlm.nih.gov/articles/PMC8637574/\n57. https://pmc.ncbi.nlm.nih.gov/articles/PMC8508774/\n58. https://pubmed.ncbi.nlm.nih.gov/16951161/\n59. https://www.nature.com/articles/6604565\n60. https://academic.oup.com/jnen/article/69/3/215/2917144",
    "citations": [
      {
        "source_id": "1",
        "source_url": "https://patents.google.com/patent/US20210363525A1/en"
      },
      {
        "source_id": "2",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10897389/"
      },
      {
        "source_id": "3",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12068844/"
      },
      {
        "source_id": "4",
        "source_url": "https://isomirtar.hse.ru"
      },
      {
        "source_id": "5",
        "source_url": "https://ouci.dntb.gov.ua/en/works/4YdZYqP7/"
      },
      {
        "source_id": "6",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/32319715/"
      },
      {
        "source_id": "7",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/36780194/"
      },
      {
        "source_id": "8",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3694230/"
      },
      {
        "source_id": "9",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9563256/"
      },
      {
        "source_id": "10",
        "source_url": "https://patents.google.com/patent/WO2021216460A1/en"
      },
      {
        "source_id": "11",
        "source_url": "https://patents.google.com/patent/US20170088898A1/en"
      },
      {
        "source_id": "12",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10274725/"
      },
      {
        "source_id": "13",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8673705/"
      },
      {
        "source_id": "14",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4774466/"
      },
      {
        "source_id": "15",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12493989/"
      },
      {
        "source_id": "16",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10778311/"
      },
      {
        "source_id": "17",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/26998052/"
      },
      {
        "source_id": "18",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6469190/"
      },
      {
        "source_id": "19",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5852601/"
      },
      {
        "source_id": "20",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4865916/"
      },
      {
        "source_id": "21",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6298400/"
      },
      {
        "source_id": "22",
        "source_url": "https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2017.00318/full"
      },
      {
        "source_id": "23",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/40649712/"
      },
      {
        "source_id": "24",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8691187/"
      },
      {
        "source_id": "25",
        "source_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.971462/full"
      },
      {
        "source_id": "26",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/38775886/"
      },
      {
        "source_id": "27",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10073803/"
      },
      {
        "source_id": "28",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4422794/"
      },
      {
        "source_id": "29",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8147444/"
      },
      {
        "source_id": "30",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/36960857/"
      },
      {
        "source_id": "31",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/39713860/"
      },
      {
        "source_id": "32",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12608687/"
      },
      {
        "source_id": "33",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/36929333/"
      },
      {
        "source_id": "34",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7164431/"
      },
      {
        "source_id": "35",
        "source_url": "https://www.nature.com/articles/s41467-025-61999-1"
      },
      {
        "source_id": "36",
        "source_url": "https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2020.00080/pdf"
      },
      {
        "source_id": "37",
        "source_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2012.00194/full"
      },
      {
        "source_id": "38",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12042361/"
      },
      {
        "source_id": "39",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6059807/"
      },
      {
        "source_id": "40",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4094829/"
      },
      {
        "source_id": "41",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10820737/"
      },
      {
        "source_id": "42",
        "source_url": "https://elifesciences.org/articles/69734"
      },
      {
        "source_id": "43",
        "source_url": "https://www.nature.com/articles/s41598-023-40425-w"
      },
      {
        "source_id": "44",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/38848215/"
      },
      {
        "source_id": "45",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5091648/"
      },
      {
        "source_id": "46",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4290697/"
      },
      {
        "source_id": "47",
        "source_url": "https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2021.727481/full"
      },
      {
        "source_id": "48",
        "source_url": "https://www.oncotarget.com/article/9744/text/"
      },
      {
        "source_id": "49",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8403340/"
      },
      {
        "source_id": "50",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8533397/"
      },
      {
        "source_id": "51",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/38553549/"
      },
      {
        "source_id": "52",
        "source_url": "https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0047846"
      },
      {
        "source_id": "53",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11240393/"
      },
      {
        "source_id": "54",
        "source_url": "https://www.nature.com/articles/s41417-020-00286-1"
      },
      {
        "source_id": "55",
        "source_url": "https://www.nature.com/articles/bjc201473"
      },
      {
        "source_id": "56",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8637574/"
      },
      {
        "source_id": "57",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8508774/"
      },
      {
        "source_id": "58",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/16951161/"
      },
      {
        "source_id": "59",
        "source_url": "https://www.nature.com/articles/6604565"
      },
      {
        "source_id": "60",
        "source_url": "https://academic.oup.com/jnen/article/69/3/215/2917144"
      }
    ],
    "duration_seconds": null
  }
}